Instytut Pomnik Centrum Zdrowia Dziecka — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

4 Recruiting

3 Completed trials

1 Countries active

8 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 1 Phase II/III: 1 Phase II: 5 Phase I (Other): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Medulloblastoma recurrent 1

Top IMPs

SIROLIMUS 5 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE 1 EMPAGLIFLOZIN 1 EVEROLIMUS 1 TRAMETINIB 1 VEDOLIZUMAB 1 VIGABATRIN 1

All trials

8 total

Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma… Pending

2025-524031-39-00 Phase I (Other) 1 country 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE…
Study of the effectiveness of drugs selected depending on the molecular profile of diffuse intrinsic pontine glioma (DIPG). Recruiting

2024-515952-19-00 Phase II 1 country SIROLIMUS; TRAMETINIB
This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (level and body resistance to … Recruiting

2023-509775-16-00 Phase II 1 country VEDOLIZUMAB
Placebo controlled study to assess the efficacy and safety of rapamycin in drug resistant epilepsy associated with tuberous sclerosis comple… Recruiting

2024-515937-13-00 Phase III 1 country SIROLIMUS
Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in … Recruiting

2024-513068-25-00 Phase II/III 1 country SIROLIMUS; VIGABATRIN
Open-label study to assess safety and efficacy of rapamycin in drugresistant epilepsy associated with mTOR pathway pathologies Ended

2024-515950-25-00 Phase II 1 country SIROLIMUS
Clinical study to assess safety and efficacy of rapamycin in paediatric high grade glioma Ended

2024-515951-39-00 Phase II 1 country SIROLIMUS
Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia. Ended

2024-512840-52-00 Phase II 1 country EMPAGLIFLOZIN

Showing 1–8 of 8 trials

← All sponsors A–Z